CNS3 leukemia
Patients with known active CNS leukemia.
Known central nervous system (CNS) leukemia.
Clinical evidence of active central nervous system leukemia;
COHORT 1: Has known active central nervous system (CNS) leukemia; subjects with previously treated CNS leukemia may participate provided that they have documented clearance of CNS leukemia and are not actively treated with intrathecal chemotherapy
COHORT 2: Has known active central nervous system (CNS) leukemia; subjects with previously treated CNS leukemia may participate provided that they have documented clearance of CNS leukemia and are not actively treated with intrathecal chemotherapy
Have active central nervous system (CNS) leukemia
Participants with known central nervous system (CNS) leukemia involvement should be excluded from this clinical trial; patients with a history of CNS leukemia that has been treated and is no longer active as judged by the treating investigator are eligible
Active central nervous system (CNS) leukemia
Active, uncontrolled central nervous system (CNS) disease including CNS leukemia
Presence of active central nervous system (CNS) leukemia. Subjects adequately treated for CNS leukemia documented by 2 consecutive cerebrospinal fluid samples negative for leukemia cells are eligible. Subjects with no history of CNS leukemia will not be required to undergo cerebrospinal fluid sampling for eligibility.
Presence of active untreated central nervous system (CNS) leukemia
Presence of known central nervous system (CNS) leukemia.
Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia
Patients with active central nervous system (CNS) leukemia eligible at the discretion of treating physician
Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia.
Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is required only if there is a clinical suspicion of CNS involvement by leukemia during screening.
Patients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible
Active central nervous system (CNS) leukemia at time of treatment
Known central nervous system (CNS) leukemia
Patients with known active uncontrolled central nervous system (CNS) leukemia.
Patients with current evidence of active central nervous system (CNS) leukemia
Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia
Patients with known active uncontrolled central nervous system (CNS) leukemia
Patients with active central nervous system leukemia or requiring maintenance intrathecal chemotherapy
If prior central nervous system (CNS) leukemia, it must be treated and in CNS CR
Symptomatic and refractory central nervous system (CNS) leukemia
Active leukemia in the central nervous system (CNS)
Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
Patients must not have active central nervous system leukemia; patients with history of central nervous system (CNS) leukemia with no evidence of active CNS disease may be enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement with leukemia is allowed with approval from the study supporter
Individuals with CNS 3 leukemia
Active central nervous system leukemia
Active and/or untreated central nervous system (CNS) leukemia
Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia
Clinically active central nervous system leukemia.
Clinical evidence of active central nervous system (CNS) leukemia requiring active therapy; prior CNS leukemia well-controlled by ongoing therapy is allowed
Active central nervous system (CNS) leukemia
Patients who have active central nervous system (CNS) disease; patients with previously treated leptomeningeal disease without evidence of remaining leukemia cells by spinal fluid will be eligible
No evidence of extramedullary leukemia, such as central nervous system (CNS) or soft tissue involvement
Presence of leukemia in the central nervous system (CNS)
Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
Have active central nervous system (CNS) leukemia
Presence of leukemia in the central nervous system (CNS)
Active central nervous system (CNS) leukemia at time of HCT
Evidence of active extramedullary disease (including central nervous system [CNS] leukemia)
Active central nervous system (CNS) leukemia at time of HSCT
Clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia
Clinically active central nervous system (CNS) leukemia;
CNS leukemia
Has central nervous system (CNS) involvement of leukemia or a history of CNS leukemia
Known central nervous system leukemia
Known clinically active central nervous system (CNS) leukemia
Known clinically active central nervous system(CNS) leukemia
Who have active central nervous system (CNS) disease; patients with previously treated leptomeningeal disease without evidence of remaining leukemia cells by spinal fluid will be eligible
Patients with known or suspected central nervous system (CNS) leukemia are not eligible
Patients with known central nervous system infiltration with leukemia
Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
Subjects must not have evidence of active leukemia in the central nervous system (CNS)
Active central nervous system (CNS) leukemia
Patients with suspected or proven central nervous system (CNS) leukemia; (diagnostic lumbar puncture not required before enrollment)
Active or suspicion of central nervous system (CNS) leukemia
Subject has clinically active central nervous system leukemia.
Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is a clinical suspicion of CNS involvement by leukemia during screening.
Known CNS lymphoma or leukemia.
Known CNS lymphoma or leukemia.
Active CNS leukemia
Proven Central Nervous System (CNS) leukemia
Patients with known active uncontrolled central nervous system (CNS) leukemia.
Patients with symptomatic CNS leukemia or patients with poorly controlled CNS leukemia
Evidence of active central nervous system (CNS) leukemia
Patients with active/uncontrolled central nervous system (CNS) leukemia
Subject has clinically active central nervous system leukemia.
Active central nervous system (CNS) leukemia or known CNS leukemia.
Central nervous system (CNS) leukemia
Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
Patient has central nervous system leukemia
Clinical evidence of active central nervous system (CNS) leukemia
Subject has clinically active central nervous system leukemia.
Clinical evidence of active central nervous system leukemia at the time of screening
Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia.
Active central nervous system (CNS) leukemia within two weeks of registration; patients with a history of CNS leukemia must have adequate treatment as defined by at least two negative spinal fluid assessments separated by at least one week; patients who have received cranial radiation therapy (XRT) must still be eligible to receive total body irradiation to 4 Gy
Clinical evidence of active CNS leukemia
Patient must not have known central nervous system (CNS) leukemia
Active central nervous system (CNS) leukemia
Known clinically active central nervous system (CNS) leukemia
Presence of leukemia in the central nervous system (CNS)
Patients with active and/or untreated central nervous system (CNS) leukemia will not be eligible
Active or prior central nervous system (CNS) leukemia, unless in complete remission for at least 3 months
Active central nervous system (CNS) leukemia at time of treatment
Active central nervous system (CNS) leukemia
Active, symptomatic central nervous system (CNS) leukemia;
Patients with known active central nervous system (CNS) leukemia
Previous central nervous system leukemia
Patients with symptomatic central nervous system (CNS) leukemia or patients with poorly controlled central nervous system leukemia
Active central nervous system (CNS) leukemia
Known active central nervous system (CNS) leukemia.
Patients with known active central nervous system (CNS) leukemia will be excluded from this clinical study
Known active leukemia of the central nervous system
Presence of central nervous system (CNS) leukemia.
Current CNS Leukemia
Known clinically active CNS leukemia
If prior central nervous system (CNS) leukemia, it must be treated and in CNS complete remission (CR)
Subject has clinically active central nervous system leukemia
Current evidence of central nervous system (CNS) leukemia
The patient has known active or suspected central nervous system (CNS) leukemia. If suspected, CNS leukemia should be ruled out with relevant imaging and/or examination of cerebrospinal fluid.
For participants with leukemia, has overt central nervous system (CNS) disease (CNS 3 status).
If prior central nervous system (CNS) leukemia, it must be treated and have no evidence of CNS disease
CNS leukemia.
Active central nervous system (CNS) leukemia or known chloromatous disease
Active central nervous system (CNS) leukemia
Overt central nervous system manifestations of leukemia at diagnosis
Clinical evidence of central nervous system (CNS) or pulmonary leukostasis, or CNS leukemia
Has presence of central nervous system (CNS) involvement of leukemia or a history of CNS leukemia
Subject has clinically active central nervous system leukemia.
Known active or suspected central nervous system (CNS) leukemia.
Patients with active central nervous system leukemia are excluded from this clinical trial; patients with a history of central nervous system (CNS) leukemia but no active disease at the time of enrollment are eligible; the absence of CNS disease must be confirmed by flow cytometric and cytologic examination of the cerebrospinal fluid (CSF) within 7 days of study enrollment
CNS leukemia
Subjects with clinical symptoms suggesting active central nervous system (CNS) leukemia or known CNS leukemia. Evaluation of cerebrospinal fluid is only required if there is clinical suspicion of CNS involvement by leukemia during screening.
Known active central nervous system (CNS) leukemia.